HEADER OXIDOREDUCTASE 01-FEB-10 3LN3 TITLE CRYSTAL STRUCTURE OF PUTATIVE REDUCTASE (NP_038806.2) FROM MUS TITLE 2 MUSCULUS AT 1.18 A RESOLUTION COMPND MOL_ID: 1; COMPND 2 MOLECULE: DIHYDRODIOL DEHYDROGENASE; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: PUTATIVE REDUCTASE; COMPND 5 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: MUS MUSCULUS; SOURCE 3 ORGANISM_COMMON: MOUSE; SOURCE 4 ORGANISM_TAXID: 10090; SOURCE 5 GENE: AKR1C13, DDH; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: HK100; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: SPEEDET KEYWDS PUTATIVE REDUCTASE, STRUCTURAL GENOMICS, JOINT CENTER FOR STRUCTURAL KEYWDS 2 GENOMICS, JCSG, PROTEIN STRUCTURE INITIATIVE, PSI-2, OXIDOREDUCTASE EXPDTA X-RAY DIFFRACTION AUTHOR JOINT CENTER FOR STRUCTURAL GENOMICS (JCSG) REVDAT 3 17-JUL-19 3LN3 1 REMARK LINK REVDAT 2 01-NOV-17 3LN3 1 REMARK REVDAT 1 16-FEB-10 3LN3 0 JRNL AUTH JOINT CENTER FOR STRUCTURAL GENOMICS (JCSG) JRNL TITL CRYSTAL STRUCTURE OF PUTATIVE REDUCTASE (NP_038806.2) FROM JRNL TITL 2 MUS MUSCULUS AT 1.18 A RESOLUTION JRNL REF TO BE PUBLISHED JRNL REFN REMARK 2 REMARK 2 RESOLUTION. 1.18 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.5.0053 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD WITH PHASES REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.18 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 28.90 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 97.8 REMARK 3 NUMBER OF REFLECTIONS : 110769 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.132 REMARK 3 R VALUE (WORKING SET) : 0.131 REMARK 3 FREE R VALUE : 0.156 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 5543 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.18 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.21 REMARK 3 REFLECTION IN BIN (WORKING SET) : 6249 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 78.52 REMARK 3 BIN R VALUE (WORKING SET) : 0.2270 REMARK 3 BIN FREE R VALUE SET COUNT : 312 REMARK 3 BIN FREE R VALUE : 0.2800 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2608 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 67 REMARK 3 SOLVENT ATOMS : 395 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 7.92 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 12.41 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.03000 REMARK 3 B22 (A**2) : 0.39000 REMARK 3 B33 (A**2) : -0.39000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : -0.21000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.033 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.033 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.021 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 1.046 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.978 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.973 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 2960 ; 0.014 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): 2016 ; 0.001 ; 0.020 REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 4081 ; 1.827 ; 2.036 REMARK 3 BOND ANGLES OTHERS (DEGREES): 4980 ; 0.992 ; 3.000 REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 382 ; 5.467 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 132 ;35.170 ;24.697 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 569 ;13.812 ;15.272 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 16 ;16.205 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 473 ; 0.200 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 3205 ; 0.010 ; 0.021 REMARK 3 GENERAL PLANES OTHERS (A): 553 ; 0.001 ; 0.020 REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 1708 ; 1.753 ; 2.000 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): 672 ; 0.813 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 2811 ; 2.466 ; 3.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 1252 ; 2.533 ; 2.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 1238 ; 3.650 ; 3.000 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): 4976 ; 1.365 ; 3.000 REMARK 3 SPHERICITY; FREE ATOMS (A**2): 405 ; 7.262 ; 3.000 REMARK 3 SPHERICITY; BONDED ATOMS (A**2): 4882 ; 2.979 ; 3.000 REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : BABINET MODEL WITH MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.40 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS 1.HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS. REMARK 3 2.A MET-INHIBITION PROTOCOL WAS USED FOR SELENOMETHIONINE REMARK 3 INCORPORATION DURING PROTEIN EXPRESSION. THE OCCUPANCY OF THE SE REMARK 3 ATOMS IN THE MSE RESIDUES WAS REDUCED TO 0.75 FOR THE REDUCED REMARK 3 SCATTERING POWER DUE TO PARTIAL S-MET INCORPORATION. 3.SULFATE REMARK 3 (SO4) FROM THE CRYSTALLIZATION SOLUTION HAS BEEN MODELED IN THE REMARK 3 SOLVENT STRUCTURE. 4.ENDOGENOUS NICOTINAMIDE ADENINE REMARK 3 DINUCLEOTIDE (NAD), WHICH IS THE EXPECTED COFACTOR FOR THIS REMARK 3 PROTEIN, HAS BEEN MODELED AT THE PUTATIVE ACTIVE SITE. THE NAD REMARK 3 SHOWS SOME DISORDER IN THE STRUCTURE. 5.(4R)-2-METHYLPENTANE-2,4- REMARK 3 DIOL (MRD), WHICH MAY BE A SUBSTRATE MIMIC, HAS BEEN MODELED IN REMARK 3 THE PUTATIVE ACTIVE SITE BASED ON THE ELECTRON DENSITY. HOWEVER, REMARK 3 IT IS POSSIBLE THAT THIS MAY BE SOME OTHER COMPOUND. 6.THE REMARK 3 PROTEIN WAS SUBJECTED TO REDUCTIVE METHYLATION PRIOR TO REMARK 3 CRYSTALLIZATION. LYSINE 84 APPEARS TO HAVE BEEN PROTECTED FROM REMARK 3 REDUCTIVE METHYLATION AND WAS MODELED AS LYSINE. ALL OTHER REMARK 3 LYSINES HAVE BEEN MODELED AS N-DIMETHYL-LYSINE (MLY). REMARK 4 REMARK 4 3LN3 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 04-FEB-10. REMARK 100 THE DEPOSITION ID IS D_1000057481. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 05-NOV-09 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SSRL REMARK 200 BEAMLINE : BL9-2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.97931 REMARK 200 MONOCHROMATOR : DOUBLE CRYSTAL MONOCHROMATOR REMARK 200 OPTICS : FLAT COLLIMATING MIRROR, TOROID REMARK 200 FOCUSING MIRROR REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARMOSAIC 325 MM CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XSCALE REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 110769 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.180 REMARK 200 RESOLUTION RANGE LOW (A) : 28.895 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 95.0 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : 0.06400 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 6.2300 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.18 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.22 REMARK 200 COMPLETENESS FOR SHELL (%) : 67.4 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.45700 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 1.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: SAD REMARK 200 SOFTWARE USED: SHELX, SHELXD, AUTOSHARP REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 46.17 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.29 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 2.4000M AMMONIUM SULFATE, 0.1M TRIS PH REMARK 280 8.0, NANODROP, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 78.75300 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 23.60300 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 78.75300 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 23.60300 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: CRYSTAL PACKING ANALYSIS SUPPORTS THE ASSIGNMENT OF A REMARK 300 MONOMER AS THE SIGNIFICANT OLIGOMERIC FORM IN SOLUTION. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5650 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 26870 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -104.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 BIOMT1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 2 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 0 REMARK 465 MSE A 1 REMARK 465 SER A 2 REMARK 465 SER A 3 REMARK 465 MLY A 4 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLN A 5 CB CG CD OE1 NE2 REMARK 470 MLY A 101 CE NZ CH1 CH2 REMARK 470 GLU A 133 CD OE1 OE2 REMARK 470 GLN A 134 CG CD OE1 NE2 REMARK 470 MLY A 136 CE NZ CH1 CH2 REMARK 470 MLY A 246 CD CE NZ CH1 CH2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 OD1 ASP A 204 O HOH A 607 2.17 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 O HOH A 557 O HOH A 676 1554 2.05 REMARK 500 CH2 MLY A 33 O HOH A 574 4555 2.18 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR A 221 164.75 71.12 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 324 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 325 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 326 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NAD A 327 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MRD A 328 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 400045 RELATED DB: TARGETDB REMARK 999 REMARK 999 SEQUENCE REMARK 999 1.THIS CONSTRUCT WAS EXPRESSED WITH A PURIFICATION TAG REMARK 999 MGSDKIHHHHHHENLYFQG. THE TAG WAS REMOVED WITH TEV PROTEASE LEAVING REMARK 999 ONLY A GLYCINE (0) FOLLOWED BY THE TARGET SEQUENCE. 2.THE PROTEIN REMARK 999 WAS REDUCTIVELY METHYLATED PRIOR TO CRYSTALLIZATION. DBREF 3LN3 A 1 323 UNP Q54A37 Q54A37_MOUSE 1 323 SEQADV 3LN3 GLY A 0 UNP Q54A37 EXPRESSION TAG SEQRES 1 A 324 GLY MSE SER SER MLY GLN HIS CYS VAL MLY LEU ASN ASP SEQRES 2 A 324 GLY HIS LEU ILE PRO ALA LEU GLY PHE GLY THR TYR MLY SEQRES 3 A 324 PRO MLY GLU VAL PRO MLY SER MLY SER LEU GLU ALA ALA SEQRES 4 A 324 CYS LEU ALA LEU ASP VAL GLY TYR ARG HIS VAL ASP THR SEQRES 5 A 324 ALA TYR ALA TYR GLN VAL GLU GLU GLU ILE GLY GLN ALA SEQRES 6 A 324 ILE GLN SER MLY ILE MLY ALA GLY VAL VAL MLY ARG GLU SEQRES 7 A 324 ASP LEU PHE VAL THR THR LYS LEU TRP CYS THR CYS PHE SEQRES 8 A 324 ARG PRO GLU LEU VAL MLY PRO ALA LEU GLU MLY SER LEU SEQRES 9 A 324 MLY MLY LEU GLN LEU ASP TYR VAL ASP LEU TYR ILE MSE SEQRES 10 A 324 HIS TYR PRO VAL PRO MSE MLY SER GLY ASP ASN ASP PHE SEQRES 11 A 324 PRO VAL ASN GLU GLN GLY MLY SER LEU LEU ASP THR VAL SEQRES 12 A 324 ASP PHE CYS ASP THR TRP GLU ARG LEU GLU GLU CYS MLY SEQRES 13 A 324 ASP ALA GLY LEU VAL MLY SER ILE GLY VAL SER ASN PHE SEQRES 14 A 324 ASN HIS ARG GLN LEU GLU ARG ILE LEU ASN MLY PRO GLY SEQRES 15 A 324 LEU MLY TYR MLY PRO VAL CYS ASN GLN VAL GLU CYS HIS SEQRES 16 A 324 LEU TYR LEU ASN GLN ARG MLY LEU LEU ASP TYR CYS GLU SEQRES 17 A 324 SER MLY ASP ILE VAL LEU VAL ALA TYR GLY ALA LEU GLY SEQRES 18 A 324 THR GLN ARG TYR MLY GLU TRP VAL ASP GLN ASN SER PRO SEQRES 19 A 324 VAL LEU LEU ASN ASP PRO VAL LEU CYS ASP VAL ALA MLY SEQRES 20 A 324 MLY ASN MLY ARG SER PRO ALA LEU ILE ALA LEU ARG TYR SEQRES 21 A 324 LEU ILE GLN ARG GLY ILE VAL PRO LEU ALA GLN SER PHE SEQRES 22 A 324 MLY GLU ASN GLU MSE ARG GLU ASN LEU GLN VAL PHE GLY SEQRES 23 A 324 PHE GLN LEU SER PRO GLU ASP MSE MLY THR LEU ASP GLY SEQRES 24 A 324 LEU ASN MLY ASN PHE ARG TYR LEU PRO ALA GLU PHE LEU SEQRES 25 A 324 VAL ASP HIS PRO GLU TYR PRO PHE VAL GLU GLU TYR MODRES 3LN3 MLY A 9 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 25 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 27 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 31 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 33 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 68 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 70 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 75 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 96 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 101 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 104 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 105 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MSE A 116 MET SELENOMETHIONINE MODRES 3LN3 MSE A 122 MET SELENOMETHIONINE MODRES 3LN3 MLY A 123 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 136 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 155 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 161 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 179 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 183 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 185 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 201 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 209 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 225 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 246 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 247 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 249 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 273 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MSE A 277 MET SELENOMETHIONINE MODRES 3LN3 MSE A 293 MET SELENOMETHIONINE MODRES 3LN3 MLY A 294 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 301 LYS N-DIMETHYL-LYSINE HET MLY A 9 11 HET MLY A 25 11 HET MLY A 27 19 HET MLY A 31 11 HET MLY A 33 19 HET MLY A 68 11 HET MLY A 70 11 HET MLY A 75 11 HET MLY A 96 19 HET MLY A 101 11 HET MLY A 104 19 HET MLY A 105 11 HET MSE A 116 8 HET MSE A 122 13 HET MLY A 123 11 HET MLY A 136 7 HET MLY A 155 11 HET MLY A 161 11 HET MLY A 179 11 HET MLY A 183 19 HET MLY A 185 11 HET MLY A 201 11 HET MLY A 209 11 HET MLY A 225 11 HET MLY A 246 9 HET MLY A 247 19 HET MLY A 249 11 HET MLY A 273 11 HET MSE A 277 8 HET MSE A 293 8 HET MLY A 294 11 HET MLY A 301 11 HET SO4 A 324 5 HET SO4 A 325 5 HET SO4 A 326 5 HET NAD A 327 44 HET MRD A 328 8 HETNAM MLY N-DIMETHYL-LYSINE HETNAM MSE SELENOMETHIONINE HETNAM SO4 SULFATE ION HETNAM NAD NICOTINAMIDE-ADENINE-DINUCLEOTIDE HETNAM MRD (4R)-2-METHYLPENTANE-2,4-DIOL FORMUL 1 MLY 28(C8 H18 N2 O2) FORMUL 1 MSE 4(C5 H11 N O2 SE) FORMUL 2 SO4 3(O4 S 2-) FORMUL 5 NAD C21 H27 N7 O14 P2 FORMUL 6 MRD C6 H14 O2 FORMUL 7 HOH *395(H2 O) HELIX 1 1 PRO A 30 GLY A 45 1 16 HELIX 2 2 ALA A 52 GLN A 56 5 5 HELIX 3 3 VAL A 57 ALA A 71 1 15 HELIX 4 4 MLY A 75 LEU A 79 5 5 HELIX 5 5 TRP A 86 PHE A 90 5 5 HELIX 6 6 ARG A 91 GLU A 93 5 3 HELIX 7 7 LEU A 94 GLN A 107 1 14 HELIX 8 8 ASP A 143 ALA A 157 1 15 HELIX 9 9 ASN A 169 ASN A 178 1 10 HELIX 10 10 GLN A 199 MLY A 209 1 11 HELIX 11 11 VAL A 234 ASN A 237 5 4 HELIX 12 12 ASP A 238 MLY A 249 1 12 HELIX 13 13 SER A 251 ARG A 263 1 13 HELIX 14 14 MLY A 273 LEU A 281 1 9 HELIX 15 15 GLN A 282 PHE A 286 5 5 HELIX 16 16 SER A 289 GLY A 298 1 10 HELIX 17 17 ALA A 308 VAL A 312 5 5 SHEET 1 A 2 CYS A 7 MLY A 9 0 SHEET 2 A 2 LEU A 15 PRO A 17 -1 O ILE A 16 N VAL A 8 SHEET 1 B 9 GLY A 20 GLY A 22 0 SHEET 2 B 9 HIS A 48 ASP A 50 1 O ASP A 50 N PHE A 21 SHEET 3 B 9 PHE A 80 LEU A 85 1 O PHE A 80 N VAL A 49 SHEET 4 B 9 VAL A 111 MSE A 116 1 O ILE A 115 N LEU A 85 SHEET 5 B 9 VAL A 160 SER A 166 1 O MLY A 161 N VAL A 111 SHEET 6 B 9 CYS A 188 GLU A 192 1 O GLN A 190 N VAL A 165 SHEET 7 B 9 VAL A 212 TYR A 216 1 O VAL A 214 N VAL A 191 SHEET 8 B 9 VAL A 266 ALA A 269 1 O LEU A 268 N ALA A 215 SHEET 9 B 9 GLY A 20 GLY A 22 1 N GLY A 20 O PRO A 267 LINK C VAL A 8 N MLY A 9 1555 1555 1.33 LINK C MLY A 9 N LEU A 10 1555 1555 1.32 LINK C TYR A 24 N MLY A 25 1555 1555 1.33 LINK C MLY A 25 N PRO A 26 1555 1555 1.34 LINK C PRO A 26 N MLY A 27 1555 1555 1.33 LINK C MLY A 27 N GLU A 28 1555 1555 1.33 LINK C PRO A 30 N MLY A 31 1555 1555 1.33 LINK C MLY A 31 N SER A 32 1555 1555 1.33 LINK C SER A 32 N MLY A 33 1555 1555 1.33 LINK C MLY A 33 N SER A 34 1555 1555 1.32 LINK C SER A 67 N MLY A 68 1555 1555 1.33 LINK C MLY A 68 N ILE A 69 1555 1555 1.33 LINK C ILE A 69 N MLY A 70 1555 1555 1.33 LINK C MLY A 70 N ALA A 71 1555 1555 1.33 LINK C VAL A 74 N MLY A 75 1555 1555 1.33 LINK C MLY A 75 N ARG A 76 1555 1555 1.33 LINK C VAL A 95 N MLY A 96 1555 1555 1.34 LINK C MLY A 96 N PRO A 97 1555 1555 1.34 LINK C GLU A 100 N MLY A 101 1555 1555 1.33 LINK C MLY A 101 N SER A 102 1555 1555 1.33 LINK C LEU A 103 N MLY A 104 1555 1555 1.33 LINK C MLY A 104 N MLY A 105 1555 1555 1.34 LINK C MLY A 105 N LEU A 106 1555 1555 1.33 LINK C ILE A 115 N MSE A 116 1555 1555 1.33 LINK C MSE A 116 N HIS A 117 1555 1555 1.34 LINK C PRO A 121 N MSE A 122 1555 1555 1.33 LINK C MSE A 122 N MLY A 123 1555 1555 1.32 LINK C MLY A 123 N SER A 124 1555 1555 1.33 LINK C GLY A 135 N MLY A 136 1555 1555 1.34 LINK C MLY A 136 N SER A 137 1555 1555 1.33 LINK C CYS A 154 N MLY A 155 1555 1555 1.32 LINK C MLY A 155 N ASP A 156 1555 1555 1.32 LINK C VAL A 160 N MLY A 161 1555 1555 1.34 LINK C MLY A 161 N SER A 162 1555 1555 1.33 LINK C ASN A 178 N MLY A 179 1555 1555 1.32 LINK C MLY A 179 N PRO A 180 1555 1555 1.35 LINK C LEU A 182 N MLY A 183 1555 1555 1.33 LINK C MLY A 183 N TYR A 184 1555 1555 1.34 LINK C TYR A 184 N MLY A 185 1555 1555 1.33 LINK C MLY A 185 N PRO A 186 1555 1555 1.33 LINK C ARG A 200 N MLY A 201 1555 1555 1.33 LINK C MLY A 201 N LEU A 202 1555 1555 1.32 LINK C SER A 208 N MLY A 209 1555 1555 1.33 LINK C MLY A 209 N ASP A 210 1555 1555 1.33 LINK C TYR A 224 N MLY A 225 1555 1555 1.33 LINK C MLY A 225 N GLU A 226 1555 1555 1.33 LINK C ALA A 245 N MLY A 246 1555 1555 1.33 LINK C MLY A 246 N MLY A 247 1555 1555 1.33 LINK C MLY A 247 N ASN A 248 1555 1555 1.34 LINK C ASN A 248 N MLY A 249 1555 1555 1.33 LINK C MLY A 249 N ARG A 250 1555 1555 1.33 LINK C PHE A 272 N MLY A 273 1555 1555 1.33 LINK C MLY A 273 N GLU A 274 1555 1555 1.33 LINK C GLU A 276 N MSE A 277 1555 1555 1.34 LINK C MSE A 277 N ARG A 278 1555 1555 1.33 LINK C ASP A 292 N MSE A 293 1555 1555 1.32 LINK C MSE A 293 N MLY A 294 1555 1555 1.33 LINK C MLY A 294 N THR A 295 1555 1555 1.34 LINK C ASN A 300 N MLY A 301 1555 1555 1.33 LINK C MLY A 301 N ASN A 302 1555 1555 1.32 SITE 1 AC1 4 ARG A 171 ARG A 175 HOH A 360 HOH A 453 SITE 1 AC2 4 GLY A 158 MLY A 161 HOH A 507 HOH A 668 SITE 1 AC3 3 MLY A 9 MLY A 185 HOH A 677 SITE 1 AC4 30 GLY A 22 THR A 23 TYR A 24 ASP A 50 SITE 2 AC4 30 TYR A 55 LYS A 84 HIS A 117 SER A 166 SITE 3 AC4 30 ASN A 167 GLN A 190 TYR A 216 GLY A 217 SITE 4 AC4 30 ALA A 218 LEU A 219 GLY A 220 THR A 221 SITE 5 AC4 30 GLN A 222 TYR A 224 LEU A 236 ALA A 253 SITE 6 AC4 30 ALA A 269 GLN A 270 GLU A 276 GLU A 279 SITE 7 AC4 30 ASN A 280 MRD A 328 HOH A 353 HOH A 390 SITE 8 AC4 30 HOH A 567 HOH A 625 SITE 1 AC5 6 TYR A 55 HIS A 117 TYR A 118 TRP A 227 SITE 2 AC5 6 PHE A 310 NAD A 327 CRYST1 157.506 47.206 47.100 90.00 94.98 90.00 C 1 2 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.006349 0.000000 0.000554 0.00000 SCALE2 0.000000 0.021184 0.000000 0.00000 SCALE3 0.000000 0.000000 0.021312 0.00000